Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 4.93 USD -4.09%
Market Cap: 274.1m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

Foghorn Therapeutics Inc.
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Foghorn Therapeutics Inc.
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Cash & Cash Equivalents
$80.3m
CAGR 3-Years
-5%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%
No Stocks Found

Foghorn Therapeutics Inc.
Glance View

Market Cap
274.1m USD
Industry
Biotechnology

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

FHTX Intrinsic Value
6.13 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Foghorn Therapeutics Inc.'s Cash & Cash Equivalents?
Cash & Cash Equivalents
80.3m USD

Based on the financial report for Dec 31, 2023, Foghorn Therapeutics Inc.'s Cash & Cash Equivalents amounts to 80.3m USD.

What is Foghorn Therapeutics Inc.'s Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
15%

Over the last year, the Cash & Cash Equivalents growth was 54%. The average annual Cash & Cash Equivalents growth rates for Foghorn Therapeutics Inc. have been -5% over the past three years , 15% over the past five years .

Back to Top